financetom
Business
financetom
/
Business
/
BRIEF-Unilever Expects FY2025 Underlying Sales Growth To Be Within 3%-5% Range
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Unilever Expects FY2025 Underlying Sales Growth To Be Within 3%-5% Range
Jul 31, 2025 12:18 AM

July 31 (Reuters) - Unilever PLC ( UL ):

* UNILEVER PLC ( UL ) - 2025 FIRST HALF RESULTS

* UNILEVER ( UL ): ON TRACK TO DEMERGE ICE CREAM BY MID-NOVEMBER

* UNILEVER ( UL ): QUARTERLY DIVIDEND UP 3% VERSUS Q2 2024; EUR 1.5

BILLION SHARE BUYBACK COMPLETED

* UNILEVER ( UL ): IN SECOND HALF, WE EXPECT FURTHER ACCELERATION

IN

EMERGING MARKETS

* UNILEVER ( UL ): FOR FY2025, WE EXPECT UNDERLYING SALES GROWTH TO

BE

WITHIN OUR RANGE OF 3% TO 5%

* UNILEVER ( UL ): SEES SECOND HALF GROWTH AHEAD OF FIRST HALF

DESPITE

SUBDUED MARKET CONDITIONS

* UNILEVER ( UL ): MACROECONOMIC AND CURRENCY ENVIRONMENT IS

UNCERTAIN

AND WE WILL BE AGILE IN ADJUSTING OUR PLANS AS NECESSARY

* UNILEVER ( UL ): ANTICIPATE IMPROVEMENT IN UNDERLYING OPERATING

MARGIN

FOR FULL YEAR, WITH H2 MARGINS OF AT LEAST 18.5%

* UNILEVER ( UL ): FOR FY 2025, WE ANTICIPATE RESTRUCTURING COSTS

OF

AROUND 1.4% OF TURNOVER

* UNILEVER ( UL ): QUARTERLY DIVIDEND PAYABLE IN SEPT 2025 EUR

0.4528

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ionis, Otsuka Receive European Commission Approval for Hereditary Angioedema Treatment Dawnzera
Ionis, Otsuka Receive European Commission Approval for Hereditary Angioedema Treatment Dawnzera
Mar 11, 2026
07:38 AM EST, 01/21/2026 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) and Otsuka Pharmaceutical have received European Commission approval for Dawnzera, or donidalorsen, for the routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 and older, Ionis said Wednesday. Dawnzera is self-administered via subcutaneous autoinjector every four or eight weeks, the company said. The...
Netflix-Warner Bros deal could offer viewers relief from subscription fatigue
Netflix-Warner Bros deal could offer viewers relief from subscription fatigue
Mar 11, 2026
Jan 21 (Reuters) - Nick LaFleur is one of many Americans who think a Netflix-Warner Bros tie-up might provide some relief from subscription fatigue. The New York City resident has held on to a full poker hand of streaming services - Netflix ( NFLX ), Disney+, Apple TV, HBO Max and Paramount+ - even as prices have risen steadily. Netflix...
Top Premarket Decliners
Top Premarket Decliners
Mar 11, 2026
07:38 AM EST, 01/21/2026 (MT Newswires) -- Top Wealth Group ( TWG ) stock was down 28% pre-bell Wednesday, paring Tuesday's rally. Solo Brands ( SBDS ) shares were 22% lower, adding to Tuesday's decline. Galaxy Payroll Group ( GLXG ) stock was down 19%, shaving gains from the previous session. ...
Charles Schwab's Q4 Adjusted Earnings, Net Revenue Rise
Charles Schwab's Q4 Adjusted Earnings, Net Revenue Rise
Mar 11, 2026
07:40 AM EST, 01/21/2026 (MT Newswires) -- Charles Schwab ( SCHW ) reported Q4 adjusted earnings Wednesday of $1.39 per diluted share, up from $1.01 a year earlier. Analysts polled by FactSet expected $1.40. Net revenue for the quarter ended Dec. 31 was $6.34 billion, compared with $5.33 billion a year earlier. Analysts surveyed by FactSet expected $6.38 billion. Charles...
Copyright 2023-2026 - www.financetom.com All Rights Reserved